<DOC>
	<DOCNO>NCT02445209</DOCNO>
	<brief_summary>The purpose study compare efficacy safety palliative chemotherapy EOX mDCF regimens first-line treatment patient advance HER2-negative gastric gastroesophageal junction ( GEJ ) adenocarcinoma</brief_summary>
	<brief_title>Comparison Efficacy Frequency Adverse Events 1st Line Palliative Chemotherapy EOX mDCF Regimens Advanced HER2-negative Gastric Carcinoma</brief_title>
	<detailed_description>The main purpose : determine overall survival ( OS ) patient locally advance inoperable metastatic HER2-negative gastric gastroesophageal adenocarcinoma treat first-line EOX ( epirubicin + oxaliplatin + capecitabine ) mDCF ( docetaxel + cisplatin + leucovorin + 5fluorouracil ) palliative chemotherapy regimens The secondary purpose : determine safety ( assessed adverse event accord Common Terminology Criteria Adverse Events ( CTCAE ) v4.0 ) progression-free survival ( PFS )</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<criteria>Patients â‰¥ 18 year histologically confirm inoperable locally advanced , recurrent , metastatic adenocarcinoma stomach gastrooesophageal junction ; ECOG ( Eastern Cooperative Oncology Group ) performance status 02 ; adequate renal , hepatic , hematologic function ; measurable nonmeasurable disease accord Response Evaluation Criteria Solid Tumors ( RECIST ) . Patients intraoperatively confirm intraperitoneal metastasis without detectable disease radiological study also eligible HER2 positive tumor define either IHC 3+ IHC 2+ , latter combination FISH+ previous chemotherapy metastatic locally advanced disease surgery &lt; 3 week onset study treatment congestive heart failure significant dysphagia would preclude oral administration capecitabine concurrent malignant disease , except adequately treat tumor high likelihood cure ( e.g . basal cell carcinoma skin , cervical cancer ) clinical evidence brain metastasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>HER2-negative gastric GEJ adenocarcinoma</keyword>
	<keyword>first-line palliative chemotherapy</keyword>
	<keyword>EOX</keyword>
	<keyword>mDCF</keyword>
	<keyword>efficacy</keyword>
	<keyword>safety</keyword>
</DOC>